Table 1 |
|||
|
PDE-5 inhibitor trials by condition (percent of total) |
|||
|
Condition |
Sildenafil |
Tadalafil |
Vardenafil |
|
|
|||
|
Mixed aetiology |
67 |
75 |
73 |
|
Diabetes |
14 |
11 |
13 |
|
Prostatectomy |
0.0 |
15 |
13 |
|
Depression |
5.7 |
0.0 |
0.0 |
|
Spinal cord injury |
5.3 |
0.0 |
0.0 |
|
Multiple sclerosis |
3.1 |
0.0 |
0.0 |
|
Coronary heart disease |
2.1 |
0.0 |
0.0 |
|
Radiotherapy for prostate cancer |
1.7 |
0.0 |
0.0 |
|
Renal failure and haemodialysis |
1.0 |
0.0 |
0.0 |
|
Rectal surgery |
0.5 |
0.0 |
0.0 |
|
Spina bifida |
0.5 |
0.0 |
0.0 |
|
|
|||
|
Moore et al. BMC Urology 2005 5:18 doi:10.1186/1471-2490-5-18 |
|||
